What is the mechanism of action of vericiguat in heart failure and what is the recommended dosing regimen?

Vericiguat Mechanism of Action and Dosing in Heart Failure

Vericiguat is a soluble guanylate cyclase (sGC) stimulator that directly enhances cyclic GMP production, leading to vasodilation, improved endothelial function, and reduced cardiac fibrosis and remodeling; it should be initiated at 2.5 mg once daily and titrated to a target dose of 10 mg once daily in patients with worsening HFrEF.

Mechanism of Action

Vericiguat works through a dual mechanism targeting the impaired nitric oxide (NO)-sGC-cyclic guanosine monophosphate (cGMP) pathway that is characteristic of heart failure 1:

• Direct sGC stimulation: Vericiguat directly binds to and stimulates sGC, increasing intracellular cGMP production independently of NO availability 2, 1
• NO sensitization: It enhances the sensitivity of sGC to endogenous NO, working synergistically with whatever NO is present 3, 1
• Downstream effects: The increased cGMP leads to smooth muscle relaxation, vasodilation, improved endothelial function, and reduction in myocardial fibrosis and adverse cardiac remodeling 2

This mechanism is particularly relevant because heart failure is associated with impaired NO synthesis and decreased sGC activity, contributing to progressive myocardial and vascular dysfunction 1.

Recommended Dosing Regimen

Starting dose: 2.5 mg once daily 4, 1

Titration schedule: Double the dose approximately every 2 weeks as tolerated 4, 1

Target dose: 10 mg once daily 2, 4, 1

Administration: Take with food to optimize absorption (93% bioavailability when taken with food) 1

Dosing Advantages

Vericiguat offers several practical benefits that make it particularly suitable for complex patients 5:

• Once-daily administration improves compliance
• No routine laboratory monitoring required
• No therapeutic drug monitoring needed
• Reaches steady-state after approximately 6 days 1
• Target dose achieved in 89% of patients in the VICTORIA trial 2

Patient Selection Criteria

Vericiguat should be considered specifically for patients with:

• LVEF <45% 2
• NYHA class II-IV symptoms 2
• Recent worsening heart failure defined as:
  • Hospitalization for HF within the past 6 months, OR
  • Recent outpatient IV diuretic therapy 2, 3, 2
• Elevated natriuretic peptides:
  • BNP ≥300 pg/mL (sinus rhythm) or higher cutoffs with atrial fibrillation
  • NT-proBNP ≥1000 pg/mL (sinus rhythm) or higher cutoffs with atrial fibrillation 2
• Already on guideline-directed medical therapy (GDMT) 2, 3, 2

Exclusions and Contraindications

Do not initiate vericiguat in patients with:

• Systolic blood pressure <100 mm Hg 2
• eGFR <15 mL/min/1.73 m² 2, 1
• Patients on dialysis 1
• Severe hepatic impairment (Child-Pugh C) 1

Use caution with:

• Concomitant long-acting nitrates (limited experience) 1
• PDE-5 inhibitors (additional BP reduction of up to 5.4 mm Hg observed) 1

Clinical Efficacy and Positioning

The VICTORIA trial demonstrated that vericiguat reduces the composite endpoint of cardiovascular death or HF hospitalization by 10% (HR 0.90,95% CI 0.83-0.98, p=0.019) 2. This benefit was primarily driven by reduction in HF hospitalizations (HR 0.90,95% CI 0.81-1.00) rather than cardiovascular mortality (HR 0.93,95% CI 0.81-1.07, not statistically significant) 2.

Important Nuances

Patient characteristics matter: Subgroup analysis revealed heterogeneity in treatment response 2:

• Patients with NT-proBNP >5314 pg/mL (highest quartile) did not benefit from vericiguat 2
• Patients with very high NT-proBNP >8000 pg/mL showed attenuated response 3
• Greatest benefit observed in patients with lower baseline natriuretic peptide levels 3

Guideline recommendations: The 2022 AHA/ACC/HFSA guidelines and 2021 CCS/CHFS guidelines provide conditional recommendations for vericiguat as add-on therapy in this high-risk population 2, 3, 2. It is positioned as an additional therapy for patients with worsening HFrEF despite GDMT, not as a replacement for foundational therapies like ARNI or SGLT2 inhibitors 6.

Safety Profile

Vericiguat was generally well-tolerated in the VICTORIA trial 2:

• Symptomatic hypotension: 9.1% vs 7.9% with placebo (p=0.12, not statistically significant)
• Syncope: 4.0% vs 3.5% with placebo (p=0.30, not statistically significant)
• Mean systolic BP reduction: approximately 1-2 mm Hg greater than placebo 1
• No clinically significant renal dysfunction despite low eGFR cutoff for enrollment 3

Special Populations

Elderly patients: No dose adjustment required; well-tolerated in patients ≥65 years (63% of VICTORIA cohort) and ≥75 years (31% of cohort) 1

Renal impairment: No dose adjustment needed for eGFR ≥15 mL/min/1.73 m² 1

Hepatic impairment: No adjustment for Child-Pugh A or B; not studied in Child-Pugh C 1

Clinical Positioning

Vericiguat should be viewed as a risk-targeted, mechanistically complementary add-on therapy for high-risk patients with recent decompensation, not as a foundational pillar of HFrEF therapy 7. It fills a specific niche for patients who remain at high risk despite optimization of neurohormonal blockade with ARNI, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors. The modest but clinically relevant 10% relative risk reduction is most meaningful in the vulnerable post-hospitalization period when event rates are highest 3.